Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-23
- Development stage
- Unknown
- Lead developer
- Curanter
- Administration
- Oral
01
Overview
CH-23 is a homeopathic remedy produced by Curanter Homeo, a company based in Patna, India. It is part of a product line (CH-19 through CH-31) sold as finished retail goods in the form of oral drops and tablets. As a homeopathic preparation, it lacks a defined pharmacological mechanism of action, and there is no clinical trial data or R&D pipeline information available for the product. It is marketed for general use within the framework of homeopathic medicine and is sold directly to consumers via the company's e-commerce platform.
- Brand names
- CH-23CH23CH 23
- Other names
- CH-23 dropsCH23 dropsCH 23 dropsCH-23 tabletsCH23 tabletsCH 23 tablets
Beyond the preview
Go deeper on CH-23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH-23.